Anti‐tumor responses have been reported in both mice and humans, and there is a general consensus that CD40 agonist therapy provides the necessary immune‐priming signals to convert the immunogenic cold tumor microenvironment to a desirable hot inflammatory microenvironment.17 The gene discussed is CD40; the disease is neoplasm.